Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Jogender Tushir-Singh. (2017) Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy. Expert Opinion on Biological Therapy 17:3, pages 325-338.
Read now
Read now
Myrna R Nahas & Jon E Arnason. (2015) Targeting CD20 in chronic lymphocytic leukemia. Blood and Lymphatic Cancer: Targets and Therapy 5, pages 43-53.
Read now
Read now
Aisha Masood, Taimur Sher, Aneel Paulus, Kena C Miller, Kasyapa S Chitta & Asher Chanan-Khan. (2011) Targeted treatment for chronic lymphocytic leukemia. OncoTargets and Therapy 4, pages 169-183.
Read now
Read now
Jack D Burton & David M Goldenberg. (2010) New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma. Expert Opinion on Emerging Drugs 15:4, pages 569-583.
Read now
Read now
Articles from other publishers (11)
Yujun Zeng, Yufan Xiang, Ruilong Sheng, Helena Tomás, João Rodrigues, Zhongwei Gu, Hu Zhang, Qiyong Gong & Kui Luo. (2021) Polysaccharide-based nanomedicines for cancer immunotherapy: A review. Bioactive Materials 6:10, pages 3358-3382.
Crossref
Crossref
Jeff P. Sharman. (2019) Targeting CD20: teaching an old dog new tricks. Hematology 2019:1, pages 273-278.
Crossref
Crossref
Nikolaos Papadantonakis & Anjali S. Advani. (2016) Recent advances and novel treatment paradigms in acute lymphocytic leukemia. Therapeutic Advances in Hematology 7:5, pages 252-269.
Crossref
Crossref
Nele Claes, Judith Fraussen, Piet Stinissen, Raymond Hupperts & Veerle Somers. (2015) B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions. Frontiers in Immunology 6.
Crossref
Crossref
Keguan Chen, Jerry G. Page, Ann M. Schwartz, Thomas N. Lee, Stephen L. DeWall, Daniel J. Sikkema & Catherine Wang. (2013) False-positive immunogenicity responses are caused by CD20+ B cell membrane fragments in an anti-ofatumumab antibody bridging assay. Journal of Immunological Methods 394:1-2, pages 22-31.
Crossref
Crossref
Michinori Ogura, Kiyohiko Hatake, Kensei Tobinai, Toshiki Uchida, Tatsuya Suzuki, Yasuhito Terui, Masahiro Yokoyama, Dai Maruyama, Masakazu Mori, Roxanne C. Jewell, Koichi Katsura & Tomomitsu Hotta. (2013) Phase I Study of Ofatumumab, a Human Anti-CD20 Antibody, in Japanese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. Japanese Journal of Clinical Oncology 43:5, pages 466-475.
Crossref
Crossref
Rangaiah Shashidharamurthy, Erica N. Bozeman, Jaina Patel, Ramneet Kaur, Jeyandra Meganathan & Periasamy Selvaraj. (2011) Immunotherapeutic strategies for cancer treatment: A novel protein transfer approach for cancer vaccine development. Medicinal Research Reviews 32:6, pages 1197-1219.
Crossref
Crossref
Ira V. Gupta & Roxanne C. Jewell. (2012) Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies. Annals of the New York Academy of Sciences 1263:1, pages 43-56.
Crossref
Crossref
Alan S. Wayne. 2013. Childhood Leukemias. Childhood Leukemias
563
581
.
Moira Davenport & Mary Ann Howland. 2011. Challenging and Emerging Conditions in Emergency Medicine. Challenging and Emerging Conditions in Emergency Medicine
158
183
.
Robert O. Dillman. (2011) Cancer Immunotherapy. Cancer Biotherapy and Radiopharmaceuticals 26:1, pages 1-64.
Crossref
Crossref